Despite encouraging results with HD IL-2 therapy for MM and mRCC, the widespread use of HD IL-2 therapy has been hampered due to its significant toxicity, necessitating hospitalization at expert centers and limiting its use to patients with intact or minimally impaired functional status (16) (Figure 1, Table 1). Here, IL2 is linked to Miyoshi myopathy.